Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2018 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Annual Healthcare Conference

DUBLIN, Ireland and TREVOSE, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
March 05, 2018 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc to Present KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American Academy of Neurology Annual Meeting

~ Post-Hoc Analysis of Phase 3 Placebo-Controlled Study of KEVEYIS Showed Adolescents had Similar Improvements in Short-Term Attack Rates as Adults ~ ~ Pooled Analysis of Two Phase 3...
February 28, 2018 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate Update

DUBLIN, Ireland and TREVOSE, Pa., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
February 26, 2018 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional Shares

DUBLIN, Ireland and TREVOSE, Penn. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that the underwriters of its previously announced...
February 23, 2018 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders

DUBLIN, Ireland and TREVOSE, Pa., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
January 25, 2018 18:43 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, Ireland and TREVOSE, Pa., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has priced its previously announced underwritten...
January 23, 2018 16:26 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares

DUBLIN, Ireland and TREVOSE, Pa., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it intends to offer and sell 5 million of its...
January 18, 2018 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome

DUBLIN, Ireland and TREVOSE, Pa., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development...
January 17, 2018 07:00 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~ ~ MACRILEN is Strongbridge’s Second Commercial...
December 14, 2017 07:30 ET | Source: Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces New Employment Inducement Awards

DUBLIN, Ireland and TREVOSE, Pa., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...